| dbo:abstract
|
- Monomethyl auristatin F (MMAF) is a synthetic antineoplastic agent. It is part of the approved drug belantamab mafodotin in multiple myeloma and some experimental anti-cancer antibody-drug conjugates such as vorsetuzumab mafodotin and SGN-CD19A. In International Nonproprietary Names for MMAF-antibody-conjugates, the name mafodotin refers to MMAF plus its attachment structure to the antibody. (en)
- モノメチルアウリスタチンF（Monomethyl auristatin F；MMAF）は、合成抗悪性腫瘍剤である。多発性骨髄腫治療薬のや、、等一部の実験的抗がん抗体薬物複合体の一部をなす。MMAF-MAB-複合体の国際一般名では、MMAFに抗体との結合構造（下記参照）を加えたものをマホドチン（mafodotin）という。 (ja)
|
| dbo:iupacName
|
- (S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-N,3-dimethyl-2-((S)-3-methyl-2-(methylamino)butanamido)butanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanamido)-3-phenylpropanoic acid (en)
|
| dbo:thumbnail
| |
| dbo:wikiPageID
| |
| dbo:wikiPageLength
|
- 4432 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID
| |
| dbo:wikiPageWikiLink
| |
| dbp:imagefile
|
- Monomethylauristatin F.svg (en)
|
| dbp:imagesize
| |
| dbp:iupacname
| |
| dbp:wikiPageUsesTemplate
| |
| dcterms:subject
| |
| gold:hypernym
| |
| rdf:type
| |
| rdfs:comment
|
- Monomethyl auristatin F (MMAF) is a synthetic antineoplastic agent. It is part of the approved drug belantamab mafodotin in multiple myeloma and some experimental anti-cancer antibody-drug conjugates such as vorsetuzumab mafodotin and SGN-CD19A. In International Nonproprietary Names for MMAF-antibody-conjugates, the name mafodotin refers to MMAF plus its attachment structure to the antibody. (en)
- モノメチルアウリスタチンF（Monomethyl auristatin F；MMAF）は、合成抗悪性腫瘍剤である。多発性骨髄腫治療薬のや、、等一部の実験的抗がん抗体薬物複合体の一部をなす。MMAF-MAB-複合体の国際一般名では、MMAFに抗体との結合構造（下記参照）を加えたものをマホドチン（mafodotin）という。 (ja)
|
| rdfs:label
|
- モノメチルアウリスタチンF (ja)
- Monomethyl auristatin F (en)
|
| owl:sameAs
| |
| prov:wasDerivedFrom
| |
| foaf:depiction
| |
| foaf:isPrimaryTopicOf
| |
| is dbo:wikiPageRedirects
of | |
| is dbo:wikiPageWikiLink
of | |
| is foaf:primaryTopic
of | |
